Communicators

are winners!

More News

25.01.2023
RECCE - A$6.21m Received from R&D Rebate Payments
10.01.2023
Australian Patent to be Granted for RECCE® Anti-Infectives
15.12.2022
Recce Pharmaceuticals: Anti-Infective Research Unit Established at Murdoch Children’s Research Institute
09.12.2022
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study
28.10.2022
Recce Pharmaceuticals Ltd.: Quarterly Cash Flow Statement & Operational Highlights
18.10.2022
RECCE® 327 SARS-CoV-2 Study Update
27.09.2022
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs
01.09.2022
Recce Pharmaceuticals Appoints Alistair McKeough to Board of Directors
22.08.2022
Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
11.07.2022
Recce Pharmaceuticals: Appointment of Dr Philip Sutton as Vice President of Translational Sciences